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TO THE EDITOR
The vascular contribution to the
pathogenesis of psoriasis has generally
received limited attention, although
abnormalities in cutaneous vessels
in psoriatic lesions are a prominent
feature. The dermal blood vessels in
psoriatic lesions are found to be tor-
tuous, enlarged, and hyperpermeable
(Creamer et al., 2002; Heidenreich
et al., 2009). Interestingly, these micro-
vascular changes occur very early in
the development of the psoriatic lesion,
suggesting that angiogenesis is one of
the key features of psoriasis patho-
genesis (Creamer et al., 2002). In
1994, vascular endothelial growth
factor (VEGF) was identified as a major
epidermis-derived growth factor that
was strongly upregulated in skin lesions
of psoriasis (Detmar et al., 1994).
Previous studies have demonstrated
increased serum levels of VEGF in
psoriasis patients that correlated to
disease severity (Creamer et al., 1996;
Nielsen et al., 2002; Heidenreich et al.,
2009). Recently, serum levels of VEGF
and its soluble receptor sVEGFR1 were
significantly increased in psoriasis, with
the highest levels in patients with a
psoriasis area and severity index score
higher than 20 (Flisiak et al., 2008). In
contrast, we and others have demon-
strated no significant increase in VEGF
serum levels in patients with mild-to-
moderate psoriasis (Barile et al., 2006;
Anderson et al., 2010). Moreover, VEGF-
overexpressing transgenic mice displayed
an increased density of tortuous capil-
laries and were shown spontaneously to
develop an inflammatory skin disorder
resembling psoriasis (Xia et al., 2003).
The increasing evidence for the role
of VEGF in the pathogenesis of psori-
asis has led to interest in VEGF as a
modifier gene in psoriasis. Certain
genetic variants of VEGF may repre-
sent an ‘‘angiogenic constitution’’ with
an increased risk of developing psori-
asis. In line with this hypothesis, recent
studies have indicated that distinct
single-nucleotide polymorphisms (SNPs)
in the VEGF gene are linked with reduced
or increased expression levels (Watson
et al., 2000; Stevens et al., 2003).
In a large and well-defined family-
based patient sample, we have aimed
comprehensively to characterize vari-
ations throughout the VEGF gene.
Haplotype-tagging SNPs were selected
for genotyping from a 19.7 kb region
using the HapMap release 27 data
(www.hapmap.org) and the Tagger
utility of Haploview (www.broad.mit.
edu/mpg/tagger). The 19.7 kb region
r 2= 0.97
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– 634 G>C
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Figure 1. Structure of the VEGFA gene and the positions of the tSNPs analyzed in this study. tSNP, tag
single-nucleotide polymorphism; UTR, untranslational region.
Abbreviations: SNP, single-nucleotide polymorphism; VEGF, vascular endothelial growth factor
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spans 2.7 kb up- and downstream of the
VEGF gene, thereby including the
promoter region. We selected four
SNPs with a minor allele frequency of
40.2 that were in linkage disequilib-
rium with all the genetic variations
within the region. The SNPs (r2 thresh-
old 40.8) were indicated as haplotype
tagging for eight alleles present in a
white Caucasian population. The posi-
tions of the typed tagging SNPs are
shown in Figure 1. The genetic analyses
were performed using TaqMan SNP
genotyping assays (Applied Biosystems,
Foster City, CA) in a patient sample
including 491 families with 741 af-
fected individuals in a total of 1988
individuals (Inerot et al., 2005). Further-
more, 683 controls of southern Swedish
origin were analyzed. All genotypes
were shown to be in Hardy–Weinberg
equilibrium.
Using a family-based transmission
disequilibrium test, taking into account
all affected individuals, we found no
statistical difference in the transmission
of genotypes or haplotypes (Table 1a).
Severity was assessed based on the
distribution of psoriasis in nine predi-
lection sites. A one-point scale was
used, which led to a score in a range
from 0 (normal) to 9 (most wide-
spread psoriasis). Patients with a sever-
ity score above 4 were considered to
have more severe psoriasis. There were
no associations between genotypes
or haplotypes with these subgroups
(Table 1a). The analysis of haplotypes
is regarded as a complementary method
that also detects untyped SNPs that
are in linkage disequilibrium with the
typed SNPs. Genotype frequencies
were in good agreement with HapMap
data and with previous published
studies.
Next, we used a different study de-
sign, e.g., a logistic regression analysis, in
which we included all psoriasis patients
in the families as cases (N¼ 741) and
683 healthy controls. The dependencies
between family members were handled
by using the median statistic from a large
number of independent samples. Again,
no overall association was found bet-
ween any of the individual SNPs with
psoriasis. Moreover, no significant asso-
ciation was found after stratification
for gender and severity (Table 1b). The
relationship between age of onset and
VEGF genotype was examined using
linear regression analysis with HLA-
Cw6 status as covariate (Table 1c). No
significant associations were found.
There are a small number of pre-
vious studies of the association between
specific polymorphisms in VEGF and
the risk of psoriasis. These studies were
generally small case–control studies
that did not include families. Young
et al. (2004) analyzed the þ405 C/C
Table 1a. Family-based transmission disequilibrium test of genotype and
haplotype distribution
Cases: individuals with psoriasis
Transmission ratios
SNP Transm. T:U v2 P-value P prem T/U T/(U+T)
rs833068 G 259:234 1.27 0.26 0.90 1.11 0.53
rs833070 T 235:215 0.89 0.35 0.96 1.09 0.52
rs3025010 T 232:202 2.07 0.15 0.73 1.15 0.53
rs10434 G 201:184 0.75 0.39 0.97 1.09 0.52
Haplotype Freq. T:U v2 P-value P prem T/U T/(U+T)
GTCG 0.248 172.1:142.5 2.78 0.10 0.66 1.21 0.55
ACTG 0.156 113.9:121.7 0.259 0.61 1.00 0.94 0.48
ACTA 0.140 119.5:124.9 0.12 0.73 1.00 0.96 0.49
GTCA 0.129 101.3:107.9 0.206 0.65 1.00 0.94 0.48
GCTA 0.108 77.8:88.9 0.751 0.39 1.00 0.88 0.47
GTTA 0.102 85.3:89.2 0.087 0.77 1.00 0.96 0.49
GCTG 0.082 68.9:60.5 0.546 0.46 1.00 1.14 0.53
GTTG 0.028 25.3:29.4 0.307 0.58 1.00 0.86 0.46
Cases: individuals with severity 44
Transmission ratios
SNP Transm. T:U v2 P-value P prem T/U T/(U+T)
rs833068 G 66:53 1.42 0.23 0.87 1.25 0.55
rs833070 T 56:54 0.04 0.85 1.00 1.04 0.51
rs3025010 T 56:55 0.01 0.92 1.00 1.02 0.50
rs10434 G 49:47 0.04 0.84 1.00 1.04 0.51
Haplotype Freq. T:U v2 P-value P prem T/U T/(U+T)
GTCG 0.253 30.2:38.2 0.94 0.33 0.99 0.79 0.44
ACTG 0.152 29.6:27.7 0.06 0.81 1.00 1.07 0.52
ACTA 0.145 30.4:29.2 0.02 0.88 1.00 1.04 0.51
GTCA 0.123 27.8:22.8 0.50 0.48 1.00 1.22 0.55
GCTA 0.109 24.4:23.2 0.03 0.87 1.00 1.05 0.51
GTTA 0.102 22.3:16.8 0.79 0.37 0.99 1.33 0.57
GCTG 0.082 11.6:15.8 0.63 0.43 1.00 0.73 0.42
GTTG 0.028 4.7:7.2 0.55 0.46 1.00 0.65 0.39
Abbreviations: Freq., frequency; SNP, single-nucleotide polymorphism; Transm., transmission.
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genotype (rs2010963), which is an
almost perfect proxy for rs833068
analyzed in the present study (r2¼ 0.9)
in 137 patients with chronic plaque
psoriasis. It was found more frequently
in patients with severe psoriasis and
in patients with an age at onset before
40 years of age compared with healthy
controls. Later, we demonstrated a sig-
nificant association between psoriasis
and the 460TT genotype (rs833061;
an almost perfect proxy for rs833070
analyzed in the present study; r2¼0.97;
Young et al., 2006). In a small study
from Italy comprising 117 psoriasis
patients, a haplotype including 460CC
conferred a significant risk of developing
late-onset psoriasis (Barile et al., 2006).
A study from China, comprising 107
patients, showed an association with
the 405GG genotype (Wang et al.,
2008).
In this large and comprehensive
study of patients with chronic plaque
psoriasis, we present data that do not
support the hypothesis that common
genetic variations in VEGF contribute to
the pathogenesis of psoriasis. However,
the presence of rare VEGF genetic
susceptibility variants cannot be ruled
out, although the overall contribution of
such rare variants to the disease is likely
to be limited.
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TO THE EDITOR
Staphylococcus aureus is a leading
cause of human skin infections, con-
tributing to disease in both healthy and
immunocompromised individuals, also
complicating burn and surgical wound
sites and lesions of atopic dermatitis
(Lowy, 1998; Ong and Leung, 2010).
Host defense against staphylo-
coccal skin infection is multifaceted,
relying on local immunological control
through TH17 and IL-1b–driven recruit-
ment of neutrophils in addition to the
protective actions of antimicrobial pep-
tides and physical properties of the
cutaneous barrier (Miller and Cho,
2011). Pathogen virulence in staphylo-
coccal skin infection is likewise multi-
factorial (Weidenmaier et al., 2010),
relying in part on the action of
a-hemolysin, a pore-forming cytotoxin
secreted by almost all strains of
S. aureus. Hla is required for dermone-
crotic changes during infection, also
contributing to abscess size (Kennedy
et al., 2010). Immunization strategies
targeting Hla protect against dermone-
crosis (Kennedy et al., 2010); however,
the molecular mechanism by which the
toxin causes pathological disturbance
of the epithelial barrier is ill under-
stood.
We recently identified the zinc-
dependent metalloprotease ADAM10
as the cellular receptor for Hla
(Wilke and Bubeck Wardenburg,
2010). ADAM10 regulates epithelial
function through its ability to cleave
E-cadherin, severing the protein-based
adherens junction tether between adja-
cent cells (Maretzky et al., 2005).
ADAM10 knockout mice exhibit
embryonic lethality (Hartmann et al.,
2002), whereas conditional skin knock-
out of ADAM10 during gestation or
in the postnatal epidermis results
in marked dysregulation of epithelial
differentiation and barrier function
(Weber et al., 2011). To examine the
contribution of ADAM10 to skin infec-
tion, we generated conditional knock-
out mice in which exon 3 of ADAM10
is flanked by loxP sites (Tian et al.,
2008), excised in the presence of a Cre
recombinase expressed under control
of the keratin 14 promoter (Vasioukhin
et al., 1999). Topical application of
tamoxifen to a 1-cm2 skin area for 5
days leads to localized ADAM10 geno-
mic excision (Supplementary Figure
S1a and b online), abrogating epider-
mal ADAM10 expression (Figure 1a,
ADAM10/). In contrast to litter-
mate controls, ADAM10/ mice did
not develop dermonecrotic lesions
following subcutaneous infection with
3107 colony forming units (CFUs) of
the epidemic S. aureus USA300/
LAC (Figure 1b and c). Abscess size
was reduced in ADAM10/ mice
(Figure 1d), however, lesional bacterial
recovery was unaltered (Supplementary
Figure S1c online).
The ability of ADAM10 to cleave
E-cadherin suggested that Hla may use
its receptor to cause epithelial barrier
injury, not merely to facilitate binding.
Toxin treatment of A431 keratinocytes
led to upregulation of cell-associated
metalloprotease activity measured in
a fluorogenic substrate assay; the
non-pore-forming HlaH35L mutant did
not elicit this response (Figure 1e).
Enhanced metalloprotease activity
correlated with E-cadherin cleavage,
detectable by immunoblot analysis of
E-cadherin precipitates from A431
lysates as the toxin-induced loss of
full-length protein and C-terminal frag-
ment (Ctf) accumulation produced by
ADAM10-dependent cleavage (Figure
1f). Ctf accumulation was also observed
in cultured primary keratinocytes upon
toxin treatment (Supplementary Figure
S1d online). These molecular events
occurred at subcytolytic concentrations
of Hla (10 mg per ml, data not shown),
wherein a disturbance of cell–cell inter-
actions in an A431 monolayer was
manifest as a loss of resistance to the
passage of an electrical current using
electrical cell–substrate impedance
sensing (Figure 1g).
These findings suggest that the
principal role of the toxin–receptor
complex may be to disrupt the epithelial
barrier. Within 24 hours following
S. aureus infection, loss of E-cadherinAbbreviations: CFU, colony forming unit; Ctf, C-terminal fragment
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